Breaking news

Mave Health’s Neuromodulation Headset: Pioneering A New Frontier In Mental Health Technology

by THEFUTURE.TEAM

March 18, 2026

Mave Health has introduced a $495 neuromodulation headset designed to support attention, mood regulation and stress management. The device is positioned as a consumer product and does not require medical regulatory approval.

Innovation Driven By Personal Tragedy

The company was founded in 2023 by Dhawal Jain, together with Jai Sharma and Aman Kumar. Jain said the idea was shaped by personal experience during the COVID-19 period, which highlighted challenges in measuring progress in mental health treatment. Focus shifted to neuromodulation as a way to introduce measurable outcomes in areas such as stress and productivity.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Leveraging TDCS For Lifestyle Enhancement

Rigorous Beta Testing And Preliminary Results

During private beta trials conducted between 2024 and 2025, more than 500 users reported significant improvements. Nearly 80% of participants experienced a 60% boost in productivity, while 75% noted a reduction in stress levels within two months of use. Complemented by a robust app that tracks metrics such as mood, focus, stress, and heart rate variability, the system offers insights into long-term trends, allowing both users and the company to measure its impact accurately.

Expert Perspectives And Ongoing Studies

External experts have highlighted both potential and limitations. Himanshu Nirvan, a psychiatrist who consulted on the project, pointed to the device’s accessibility and portability. Leigh Elkins Charvet of NYU Grossman School of Medicine noted that while tDCS is considered safe in controlled settings, broader consumer use requires further evidence and clearer guidelines. The company has conducted four observational studies involving 200 participants, with results currently under academic review.

Strategic Market Positioning And Investment Milestones

By marketing the headset as a non-medical lifestyle device, Mave Health aims to bypass the protracted regulatory pathways and reach a wider audience. The company’s innovative approach is supported by recent seed funding of $2.1 million led by Blume Ventures, with notable participation from investors such as Tesla Autopilot AI lead Dhaval Shroff. With under $3 million raised in total, Mave Health is set to begin shipping its first batch to customers in the U.S. and India in April 2026.

This evolution not only marks a turning point in consumer mental health technology but also underscores the broader trend of integrating advanced neuromodulation techniques into everyday wellness routines. As research continues and more clinical evidence emerges, the future of mental health management could very well be defined by such portable, scalable innovations.

The Future Forbes Realty Global Properties

Meta’s $18 Billion Settlement Limits State Claims Over Children’s Data

by News Editor

August 28, 2026

Meta’s $18 billion settlement with attorneys general from 29 U.S. states includes a provision limiting future state claims over the company’s use of children’s data for age-assurance systems.

Under the agreement, Meta must develop, train and begin testing a system to identify users under 13 within a year of the settlement taking effect. The company already uses AI-based age-detection tools, although the agreement does not require the new system to use AI.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

States Agree To Limits On Future Claims

The Children’s Online Privacy Protection Act (COPPA) generally restricts the collection and retention of personal data from children under 13. Under the settlement, the 29 state attorneys general agreed not to bring past, present or future claims under COPPA or similar state laws over the specified use of children’s data.

Meta will not be permitted to use information from users under 13 for advertising, marketing or algorithmic optimisation.

Federal Enforcement Remains Unclear

COPPA is primarily enforced by the Federal Trade Commission, which is not a party to the agreement. That leaves open the possibility of separate federal action over how Meta collects or uses children’s data.

Another issue is whether Meta can keep age-assurance data isolated from its other systems. An independent auditor will monitor compliance, but the settlement does not fully specify what data Meta can retain for training, how long it can be stored or whether derived insights can be used elsewhere.

Legal Risks Remain

Joshua Wurtzel, a partner at Schlam Stone & Dolan, said states could still pursue claims if Meta uses the data outside the settlement’s limits. Such cases could depend on how those limits are interpreted.

Peter Jackson, a data and intellectual property attorney at Greenberg Glusker, said the provision could “disincentivize future enforcement actions.”

The agreement gives Meta greater legal certainty around using children’s data for age assurance, but questions remain over federal enforcement, data retention and secondary use.